** Shares of EyePoint Pharmaceuticals rise 36.5% to five-month high of $12.96

** Co says its drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema $(DME.AU)$

** DME is an eye condition that causes blurry vision in people with diabetes

** Co expects to report the full topline results in Q1 2025

** Including session's move, EYPT stock down 50.8% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))